Prasugrel

P2Y12 inhibitor plus anti-coagulation vs. anticoagulation alone in noncritically ill patients with COVID-19.

In a cohort of noncritically ill patients with COVID-19, the addition of a P2Y12 inhibitor to anticoagulation did not extend survival or lessen disease severity, according to results of the ACTIV-4a trial.

New research from the ISAR-REACT 5 trial indicated that patients with ACS who received PCI had a lower composite endpoint of all-cause death, MI or stroke when given prasugrel vs. ticagrelor therapy.

Prasugrel and ticagrelor had similar safety and efficacy among patients with MI receiving PCI, according to results published in Heart.

Safety and efficacy of prehospital administration of crushed prasugrel (Effient, Daiichi Sankyo/Eli Lilly) vs. uncrushed tablets in patients with STEMI.

Antiplatelet therapy with ticagrelor after primary PCI for STEMI may confer similar reductions in the composite endpoint of all-cause death, MI and stroke and major bleeding compared with prasugrel, researchers reported.

In the COMPARE CRUSH trial, administration of crushed prasugrel tablets in patients with STEMI on the way to the hospital planned for primary PCI did not improve coronary reperfusion.

Net adverse clinical events in patients who underwent PCI for ACS according to aspirin-prasugrel (Effient, Daiichi Sankyo/Eli Lilly) strategy.

Ticagrelor (Brilinta, AstraZeneca) vs. prasugrel (Effient, Daiichi Sankyo/Eli Lilly) on clinical outcomes in patients with ACS undergoing a planned invasive strategy.

Among patients who underwent PCI for ACS and then had dual antiplatelet therapy with aspirin and prasugrel, halving the prasugrel dose after 1 month conferred reduced risk for net adverse clinical events, researchers reported.